leadf
logo-loader
viewMatinas BioPharma

Matinas BioPharma sees positive outcome on End of Phase 2 meeting with FDA on MAT9001's development to treat severe hypertriglyceridemia

The company said the official minutes of the meeting confirmed that it and the FDA are aligned on key next steps for MAT9001’s Phase 3 development program

Matinas BioPharma - Matinas BioPharma Holdings Inc sees positive outcome of  End of Phase 2 meeting with FDA on the development and registration pathway for MAT9001 as a omega-3 therapy
Matinas said it remains on track to initiate its Phase 3 program in the first half of 2021

Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) announced Tuesday a positive result of its End of Phase 2 meeting with the US Food and Drug Administration (FDA) on the development and registration pathway for MAT9001, a potential best-in-class prescription omega-3 therapy. 

The company said the official minutes of the meeting confirmed that it and the FDA are aligned on key next steps for MAT9001’s Phase 3 development program and registration pathway for an initial indication to treat severe hypertriglyceridemia (SHTG), a clinical disorder associated with major complications such as pancreatitis and atherosclerotic cardiovascular disease. 

Matinas, based in Bedminster, New Jersey, said it remains on track to initiate its Phase 3 program in the first half of 2021.

READ: Matinas BioPharma taps industry veteran Natasha Giordano as board director

“We are extremely pleased with the outcome of our meeting with FDA and are encouraged by the highly collaborative and strategic input we received for our program,” said Theresa Matkovits, Matinas’ chief development officer, in a statement. 

“I am very proud of what we have accomplished as a team and look forward to initiating the Phase 3 trial in SHTG and maximize the clinical opportunities for MAT9001.”

The company said it and the FDA agreed on key elements of the Phase 3 program to support a New Drug Application (NDA) filing, including the requirement for a single 12-week study to support efficacy in SHTG. 

Moreover, Matinas said the FDA provided it flexibility in the totality of patient safety data needed to meet regulatory requirements for NDA submission. The company is evaluating several ways to both meet these requirements and to potentially provide additional data differentiating MAT9001 from other prescription omega-3 drugs.

“Alignment with the FDA on our Phase 3 development program provides clarity about our development pathway for MAT9001 in SHTG,” said Matinas CEO Jerome Jabbour.

“With this important feedback from FDA, we can confidently move forward with our streamlined 505(b)2 registration for MAT9001. Our level of enthusiasm for this potential best-in-class omega-3 therapy remains high, and we look forward to forthcoming near-term data from our ongoing ENHANCE-IT head to head trial of MAT9001 vs. Vascepa to once again highlight the differentiation between these two products and the potential significant clinical benefits of MAT9001 for patients with hypertriglyceridemia and cardiovascular disease.”

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

 

 

Quick facts: Matinas BioPharma

Price: 1.04 USD

NYSE:MTNB
Market: NYSE
Market Cap: $207.22 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Matinas BioPharma named herein, including the promotion by the Company of Matinas BioPharma in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Full interview: Matinas BioPharma to begin dosing HIV patients with...

Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) CEO Jerome Jabbour tells Proactive it will begin a Part 2 study of MAT2203 for the treatment of HIV patients with cryptococcal meningitis. Jabbour explains how the New Jersey-based company will begin dosing its first patient in the...

on 02/24/2020

2 min read